Watch Ticker

Salarius Pharmaceuticals, Inc. Common Stock

Go to Salarius Pharmaceuticals, Inc. Common Stock Website

$0.60

-0.01 (-1.48%)

Live

Previous Close

$0.61

Day Range

$0 - $0

Previous Day Range

$0.59 - $0.67

Market Cap

$1.3 million USD

Day Vol.

Previous Day Vol.

646584

Currency

USD

Primary Exchange

Nasdaq

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targete...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Globe Newswire - Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Salarius Pharmaceuticals announced two animal studies supporting the potential of its drug seclidemstat in inhibiting LSD1, a target in cancer treatment. The company is progressing a clinical study at MD Anderson Cancer Center and planning a merger with Decoy Therapeutics.

Related tickers: SLRX.

Read Full Article

Delveinsight - Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight

The liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies, including immunotherapies and targeted treatments. The pipeline features 15+ companies and 20+ therapies in various stages of development.

Related tickers: AAPG, SLRX, PFE, INCY, DSNKY.

Read Full Article

Trending Tickers

Please sign in to view